Rajesh Singh to Ovarian Neoplasms
This is a "connection" page, showing publications Rajesh Singh has written about Ovarian Neoplasms.
Connection Strength
2.681
-
Kaur P, Singh SK, Mishra MK, Singh S, Singh R. Nanotechnology for boosting ovarian cancer immunotherapy. J Ovarian Res. 2024 Oct 14; 17(1):202.
Score: 0.652
-
McFadden M, Singh SK, Kinnel B, Varambally S, Singh R. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer. J Ovarian Res. 2023 Nov 21; 16(1):220.
Score: 0.613
-
Ukwade CE, Ebuehi OAT, Adisa RA, Singh SK, Singh R. Anti-proliferative activities of Byrsocarpus coccineus Schum. and Thonn. (Connaraceae) using ovarian cancer cell lines. J Ovarian Res. 2020 Jul 21; 13(1):83.
Score: 0.486
-
Singh SK, Mishra MK, Singh R. Hypoxia-inducible factor-1a induces CX3CR1 expression and promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer cells. J Ovarian Res. 2019 May 10; 12(1):42.
Score: 0.447
-
Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug; 39(2):373-81.
Score: 0.258
-
Carey KM, Young CD, Clark AJ, Dammer EB, Singh R, Lillard JW. Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment. J Ovarian Res. 2024 Dec 03; 17(1):240.
Score: 0.165
-
Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22; 8:62.
Score: 0.061